Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

A pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide and colloidal particles, said particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

• wherein said protein or polypeptide is selected from the group consisting of:
• (a) proteins or polypeptides capable of externally binding said colloidal particles;
• (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families;
• and
• (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
• wherein said protein or polypeptide is not Factor VIII (FVIII),
• and wherein said protein or polypeptide is not encapsulated in said colloidal particles.

Method of treatment of a patient suffering from a disease comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide effective in the treatment of the disease and colloidal particles, said colloidal particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

• wherein said protein or polypeptide is selected from the group consisting of:
• (a) proteins or polypeptides capable of externally binding said colloidal particles;
• (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families;
• and
• (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
• wherein said protein or polypeptide is not Factor VIII (FVIII),
• and wherein said protein or polypeptide is not encapsulated in said colloidal particles.

Method of treatment of a patient suffering from a disease comprising administrating to said patient a pharmaceutical composition for parenteral administration comprising a therapeutically effective amount of a protein or polypeptide effective in the treatment of the disease and colloidal particles, said colloidal particles comprising approximately 1-20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer,

• wherein said protein or polypeptide is selected from the group consisting of:
• (a) proteins or polypeptides capable of externally binding said colloidal particles;
• (b) proteins or polypeptides capable of binding polymers of the polyalkylether, polylactic and polyglycolic acid families;
• and
• (c) proteins or polypeptides that include a consensus sequence of S/T-X-L/I/V-I/V/Q/S-S/T-X-X-E, where X may be any amino acid, and S, T, L, I, V, E and Q have their standard meanings;
• wherein said colloidal particles and said protein or polypeptide are administered separately,
• and wherein said protein or polypeptide is not encapsulated in said colloidal particles.